Blog
RSS FeedPosted by Michael Wonder on 09 Oct 2023
Ravulizumab for the treatment of adults with generalised myasthenia gravis
4 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using ravulizumab ...
Posted by Michael Wonder on 09 Oct 2023
The evolving nature of health technology assessment: a critical appraisal of NICE’s new methods manual
6 October 2023 - NICE recently completed a review of its methods for health technology assessment, involving a 2 stage ...
Posted by Michael Wonder on 08 Oct 2023
Belumosudil mesylate for the treatment of patients with chronic graft versus host disease after two or more lines of systemic therapy
4 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Oct 2023
A decade of health innovation: the impact of new medicines on patient health and the implications for NICE’s size of benefit multiplier
6 October 2023 - This study aimed to estimate the incremental health benefits of pharmaceutical innovations approved between 2011 and 2021 ...
Posted by Michael Wonder on 05 Oct 2023
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy
3 October 2023 - Calliditas Therapeutics today announced that its partner STADA Arzneimittel has submitted a request to the MHRA of ...
Posted by Michael Wonder on 04 Oct 2023
Bimekizumab for the treatment of patients with active psoriatic arthritis
4 October 2023 - NICE has recommended evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment of ...
Posted by Michael Wonder on 04 Oct 2023
Pegunigalsidase alfa for the treatment of patients with Fabry disease
4 October 2023 - NICE has published evidence-based recommendations on the use of pegunigalsidase alfa (Elfabrio) for the treatment of ...
Posted by Michael Wonder on 03 Oct 2023
Loncastuximab tesirine for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
3 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Sep 2023
NICE draft guidance recognises potential of new targeted treatment for type of advanced breast cancer
26 September 2023 - NICE has today published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for ...
Posted by Michael Wonder on 24 Sep 2023
NICE recommends Lilly's mirikizumab (Omvoh) for the treatment of eligible adults with moderately to severely active ulcerative colitis
22 September 2023 - Eli Lilly announced today that NICE has recommended mirikizumab for the treatment of adults with moderately ...
Posted by Michael Wonder on 20 Sep 2023
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously ...
Posted by Michael Wonder on 19 Sep 2023
MHRA approves Moderna’s adapted COVID-19 vaccine (Spikevax) that targets Omicron XBB.1.5
15 September 2023 - The vaccine was approved after it was found to meet the MHRA’s standards of safety, quality and ...
Posted by Michael Wonder on 14 Sep 2023
First treatment for acute migraine to be recommended by NICE set to benefit thousands
14 September 2023 - The first treatment to be recommended by NICE for treating acute migraine will soon be available on ...
Posted by Michael Wonder on 12 Sep 2023
NICE issues two recommendations for UCB's inflammatory disease drug
11 September 2023 - NICE has issued final draft guidance recommending UCB's Bimzelx (bimekizumab), with the inflammatory disease drug now ...
Posted by Michael Wonder on 12 Sep 2023
Taking a proportionate approach to technology appraisals
12 September 2023 - In 2022, NICE introduced the first phase of a new proportionate approach to technology appraisals. ...